董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yves Huwyler | 男 | Director | 42 | 未披露 | 未持股 | 2015-04-30 |
| Lode Debrabandere | 男 | Director, President and Chief Executive Officer | 50 | 170.55万美元 | 未持股 | 2015-04-30 |
| Peter Friedli | 男 | Chairman of the Board of Directors | 61 | 9.20万美元 | 未持股 | 2015-04-30 |
| Felix Gutzwiller | 男 | Director | 77 | 6.80万美元 | 未持股 | 2015-04-30 |
| Jay M. Moyes | 男 | Chairman, Audit Committee | 61 | 6.80万美元 | 未持股 | 2015-04-30 |
| Hans Georg Klingemann | 男 | Chairman, Compensation Committee | 65 | 6.80万美元 | 未持股 | 2015-04-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan M. Hopper | 男 | Chief Medical Officer | 52 | 19.81万美元 | 未持股 | 2015-04-30 |
| Gregory I. Law | 男 | Vice President of Finance | 48 | 16.24万美元 | 未持股 | 2015-04-30 |
| Alla N. Danilkovitch | 女 | Chief Scientific Officer | 51 | 未披露 | 未持股 | 2015-04-30 |
| Philip R. Jacoby, Jr. | 男 | Chief Financial Officer, Treasurer and Secretary | 63 | 24.43万美元 | 未持股 | 2015-04-30 |
| Lode Debrabandere | 男 | Director, President and Chief Executive Officer | 50 | 170.55万美元 | 未持股 | 2015-04-30 |
| Frank D. Czworka, Jr. | 男 | Vice President and General Manager of Wound Care | 46 | 56.97万美元 | 未持股 | 2015-04-30 |
董事简历
中英对照 | 中文 | 英文- Yves Huwyler
-
Yves Huwyler，他是生物技术和技术领域的私人股本和风险投资的独立顾问。他是Huwyler Private Equity GmbH公司（私人股本服务专业公司，总部位于瑞士苏黎世）的所有者。他曾担任Friedli Corporate Finance公司的董事，直到2012年。他拥有18年以上的美国和欧洲各领域、各阶段的私募股权投资经验。他积极参与很多公司的管理。他也是Prolexys Pharmaceuticals公司的董事会成员。他曾担任领先美国和欧洲私人股本基金的咨询委员会成员。他持有the University of Zurich的经济学和金融学硕士学位。
Yves Huwyler is an independent consultant for private equity and venture investments in the area of biotechnology and technology. He is the owner of Huwyler Private Equity GmbH, a specialized firm for private equity services based in Zurich, Switzerland. Mr. Huwyler was a Director at Friedli Corporate Finance until 2012. Mr. Huwyler has over 18 years of experience in private equity investing in various sectors and at all stages, predominantly in the United States and Europe. Mr. Huwyler is actively involved in the management of a number of companies and is a member of the Board of Directors of Prolexys Pharmaceuticals, Inc. He was a member of the advisory boards of leading U.S. and European private equity funds. Mr. Huwyler holds a master degree in economics and finance from the University of Zurich. - Yves Huwyler，他是生物技术和技术领域的私人股本和风险投资的独立顾问。他是Huwyler Private Equity GmbH公司（私人股本服务专业公司，总部位于瑞士苏黎世）的所有者。他曾担任Friedli Corporate Finance公司的董事，直到2012年。他拥有18年以上的美国和欧洲各领域、各阶段的私募股权投资经验。他积极参与很多公司的管理。他也是Prolexys Pharmaceuticals公司的董事会成员。他曾担任领先美国和欧洲私人股本基金的咨询委员会成员。他持有the University of Zurich的经济学和金融学硕士学位。
- Yves Huwyler is an independent consultant for private equity and venture investments in the area of biotechnology and technology. He is the owner of Huwyler Private Equity GmbH, a specialized firm for private equity services based in Zurich, Switzerland. Mr. Huwyler was a Director at Friedli Corporate Finance until 2012. Mr. Huwyler has over 18 years of experience in private equity investing in various sectors and at all stages, predominantly in the United States and Europe. Mr. Huwyler is actively involved in the management of a number of companies and is a member of the Board of Directors of Prolexys Pharmaceuticals, Inc. He was a member of the advisory boards of leading U.S. and European private equity funds. Mr. Huwyler holds a master degree in economics and finance from the University of Zurich.
- Lode Debrabandere
-
Lode Debrabandere，2013年12月，晋升为本公司的总裁、首席执行官。他于2006年7月加入本公司，担任副总裁、治疗总经理；2012年10月，他成为首席运营官。为了填补C. Randal Mills辞职而留下的空缺，他在2014年1月当选为董事。他有着20多年的制药和生物技术行业的研发、销售及营销的领导经验。加入本公司之前，他曾担任Bristol Myers Squibb的全球营销副总裁，领导着神经科学部；也曾是Abilif的全球品牌经理。
Lode Debrabandere was promoted to serve as our President and Chief Executive Officer in December 2013. He joined us in July 2006 as our Vice President and General Manager of Therapeutics. He became our Chief Operating Officer in October 2012 and was elected to our Board of Directors in January 2014. Dr. Debrabandere has over 20-years of experience leading R&D and sales and marketing activities in the pharmaceutical and biotechnology industries. Prior to joining us, he served as Vice President of Global Marketing of Bristol Myers Squibb where he led the Neuroscience Unit and was the Global Brand Manager for Abilify™. He currently serves on the Board of Directors of Prolexys Pharmaceuticals, Inc. - Lode Debrabandere，2013年12月，晋升为本公司的总裁、首席执行官。他于2006年7月加入本公司，担任副总裁、治疗总经理；2012年10月，他成为首席运营官。为了填补C. Randal Mills辞职而留下的空缺，他在2014年1月当选为董事。他有着20多年的制药和生物技术行业的研发、销售及营销的领导经验。加入本公司之前，他曾担任Bristol Myers Squibb的全球营销副总裁，领导着神经科学部；也曾是Abilif的全球品牌经理。
- Lode Debrabandere was promoted to serve as our President and Chief Executive Officer in December 2013. He joined us in July 2006 as our Vice President and General Manager of Therapeutics. He became our Chief Operating Officer in October 2012 and was elected to our Board of Directors in January 2014. Dr. Debrabandere has over 20-years of experience leading R&D and sales and marketing activities in the pharmaceutical and biotechnology industries. Prior to joining us, he served as Vice President of Global Marketing of Bristol Myers Squibb where he led the Neuroscience Unit and was the Global Brand Manager for Abilify™. He currently serves on the Board of Directors of Prolexys Pharmaceuticals, Inc.
- Peter Friedli
-
Peter Friedli，本公司董事长，Osiris的联合创始人。他从1996年1月起，担任Osiris的董事，2004年2月至6月期间除外。1986年起，他是投资银行公司Friedli Corporate Finance的主管，这是著名的瑞士风投企业，已在生物技术行业做了重大的投资，它也是Osiris的主要融资来源。他还是New Venturetec Ltd的总裁、董事，这是瑞士的上市投资公司。作为风投行业独立的投资经理，他有着丰富的相关经验，尤其关于投资生物技术和科技行业的美国本土公司。之前，他曾从事国际管理咨询工作，为欧洲和美国的服务与工业企业提供服务。他是一些私营公司的董事。
Peter Friedli is our Chairman of the Board and was co-founder of Osiris. Mr. Friedli has been a director of Osiris since January 1996 except for the period between February and June 2004. Since 1986 he has been a principal of the investment-banking firm Friedli Corporate Finance, Inc., a leading Swiss venture capital firm which has made significant investments in the biotechnology industry and has been the primary source of financing for Osiris. Mr. Friedli is also the President and a director of New Venturetec Ltd., a Swiss publicly traded investment company. Mr. Friedli has extensive experience as an independent investment manager in venture capital and has specialized in investments domiciled in the United States in the areas of biotechnology and technology. Previously, he worked in the field of international management consulting for service and industrial companies in Europe and the United States. He serves as a director in certain private companies. - Peter Friedli，本公司董事长，Osiris的联合创始人。他从1996年1月起，担任Osiris的董事，2004年2月至6月期间除外。1986年起，他是投资银行公司Friedli Corporate Finance的主管，这是著名的瑞士风投企业，已在生物技术行业做了重大的投资，它也是Osiris的主要融资来源。他还是New Venturetec Ltd的总裁、董事，这是瑞士的上市投资公司。作为风投行业独立的投资经理，他有着丰富的相关经验，尤其关于投资生物技术和科技行业的美国本土公司。之前，他曾从事国际管理咨询工作，为欧洲和美国的服务与工业企业提供服务。他是一些私营公司的董事。
- Peter Friedli is our Chairman of the Board and was co-founder of Osiris. Mr. Friedli has been a director of Osiris since January 1996 except for the period between February and June 2004. Since 1986 he has been a principal of the investment-banking firm Friedli Corporate Finance, Inc., a leading Swiss venture capital firm which has made significant investments in the biotechnology industry and has been the primary source of financing for Osiris. Mr. Friedli is also the President and a director of New Venturetec Ltd., a Swiss publicly traded investment company. Mr. Friedli has extensive experience as an independent investment manager in venture capital and has specialized in investments domiciled in the United States in the areas of biotechnology and technology. Previously, he worked in the field of international management consulting for service and industrial companies in Europe and the United States. He serves as a director in certain private companies.
- Felix Gutzwiller
-
Felix Gutzwiller，医学博士、公共健康博士。自2003年以来，是本公司的一位董事会成员；以及是Zurich大学医学院公共卫生学院的一位荣誉教授。他还是瑞士国会大厦（Swiss Parliament）的一位选任委员。他是于1974年从Basel大学获得他的医学学位的；以及是在Harvard大学和Hopkins大学完成的他的博士后学业的。他于1980年从Johns Hopkins大学卫生和公共健康学院获得他的公共健康博士学位的。在过去的几年里，Gutzwiller博士曾获得了许多health profession的荣誉和奖项。他的丰富的健康科学领域范围经验，对Osiris董事会来说是非常宝贵的。
Felix Gutzwiller,M.D., Dr.P.H.,has been a member of our Board since 2003 and is Professor Emeritus of the Department of Public Health of the University of Zurich Medical School. Dr. Gutzwiller is also an elected member of the Swiss Parliament. Dr. Gutzwiller received a medical degree from the University of Basel in 1974 and did his post-graduate training at both Harvard University and Johns Hopkins University. He received his Dr.P.H. from the Johns Hopkins University School of Hygiene and Public Health in 1980. Dr. Gutzwiller has received many honors and awards over the years in the health profession. Dr. Gutzwiller's extensive experience across the full spectrum of the health sciences field is of significant value to the Osiris board. - Felix Gutzwiller，医学博士、公共健康博士。自2003年以来，是本公司的一位董事会成员；以及是Zurich大学医学院公共卫生学院的一位荣誉教授。他还是瑞士国会大厦（Swiss Parliament）的一位选任委员。他是于1974年从Basel大学获得他的医学学位的；以及是在Harvard大学和Hopkins大学完成的他的博士后学业的。他于1980年从Johns Hopkins大学卫生和公共健康学院获得他的公共健康博士学位的。在过去的几年里，Gutzwiller博士曾获得了许多health profession的荣誉和奖项。他的丰富的健康科学领域范围经验，对Osiris董事会来说是非常宝贵的。
- Felix Gutzwiller,M.D., Dr.P.H.,has been a member of our Board since 2003 and is Professor Emeritus of the Department of Public Health of the University of Zurich Medical School. Dr. Gutzwiller is also an elected member of the Swiss Parliament. Dr. Gutzwiller received a medical degree from the University of Basel in 1974 and did his post-graduate training at both Harvard University and Johns Hopkins University. He received his Dr.P.H. from the Johns Hopkins University School of Hygiene and Public Health in 1980. Dr. Gutzwiller has received many honors and awards over the years in the health profession. Dr. Gutzwiller's extensive experience across the full spectrum of the health sciences field is of significant value to the Osiris board.
- Jay M. Moyes
-
Jay M. Moyes，他还担任Puma Biotechnology， Inc.（一家公共生物制药公司，专注于创新产品的开发和商业化，以加强癌症治疗）的董事会成员。Moyes先生自2011年1月起担任Biocardia， Inc.（公共心血管再生医学公司）的董事会成员。从2020年3月到2023年6月，Moyes先生担任Sera Prognostics， Inc.（一家公共商业阶段的生物技术公司，专注于通过创新的生物标志物方法改善孕产妇和新生儿健康）的首席财务官。Moyes先生此前曾担任Achieve Life Sciences， Inc.（上市专业制药公司）的董事会成员（从2017年8月到2023年5月）；Predictive Technology Group, Inc.，一家公共分子诊断和再生医学公司，从2019年2月至2019年12月；Osiris Therapeutics, Inc.，一家公共生物外科公司，从2006年5月到2017年12月；2012年11月至2014年8月，他担任美国公司（现SINTX Technologies， Inc.），一家公共骨科植入物公司。2013年10月至2014年8月，他担任美国首席财务官。从2008年5月到2009年7月，Moyes先生担任XDx（现为CareDx）， Inc.（一家私营分子诊断公司）的首席财务官。在此之前，他从1996年6月到2007年11月担任Myriad Genetics， Inc.（公共医疗保健诊断公司）的首席财务官，并从1993年7月到2005年7月担任财务副总裁。从1991年到1993年，Moyes先生担任Genmark， Inc.（一家私人控股的基因公司）的财务副总裁和首席财务官。1979年至1991年，他在毕马威会计师事务所担任多个职位，最近担任高级经理。他持有Utah大学的工商管理硕士学位，Weber State大学的经济学学士学位，并曾是一名注册会计师。他也曾担任the Utah Life Science Association的董事会成员（从1999年到2006年）。
Jay M. Moyes,has also served on the board of directors of Puma Biotechnology, Inc. a public biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Mr. Moyes has been a member of the board of directors of Biocardia, Inc., a public cardiovascular regenerative medicine company, since January 2011. Mr. Moyes served as the Chief Financial Officer of Sera Prognostics, Inc., a public commercial-stage biotechnology company focused on improving maternal and neonatal health through innovative biomarker approaches, from March 2020 to June 2023. Mr. Moyes previously served as a member of the board of directors of Achieve Life Sciences, Inc., a public specialty pharmaceutical company, from August 2017 to May 2023; Predictive Technology Group, Inc., a public molecular diagnostics and regenerative medicine company, from February 2019 to December 2019; Osiris Therapeutics, Inc., a public bio-surgery company, from May 2006 until December 2017; and Amedica Corporation (now SINTX Technologies, Inc.), a public orthopedic implant company, from November 2012 to August 2014. He served as Chief Financial Officer of Amedica from October 2013 to August 2014. From May 2008 through July 2009, Mr. Moyes served as Chief Financial Officer of XDx (now CareDx), Inc., a privately held molecular diagnostics company. Prior to that, Mr. Moyes served as Chief Financial Officer of Myriad Genetics, Inc., a public healthcare diagnostics company, from June 1996 until November 2007, and as its Vice President of Finance from July 1993 until July 2005. From 1991 to 1993, Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc., a privately held genetics company. Mr. Moyes held various positions with the accounting firm of KPMG LLP from 1979 through 1991, most recently as a Senior Manager. He holds an M.B.A. from the University of Utah, a B.A. in economics from Weber State University, and is formerly a Certified Public Accountant. Mr. Moyes also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 through 2006. - Jay M. Moyes，他还担任Puma Biotechnology， Inc.（一家公共生物制药公司，专注于创新产品的开发和商业化，以加强癌症治疗）的董事会成员。Moyes先生自2011年1月起担任Biocardia， Inc.（公共心血管再生医学公司）的董事会成员。从2020年3月到2023年6月，Moyes先生担任Sera Prognostics， Inc.（一家公共商业阶段的生物技术公司，专注于通过创新的生物标志物方法改善孕产妇和新生儿健康）的首席财务官。Moyes先生此前曾担任Achieve Life Sciences， Inc.（上市专业制药公司）的董事会成员（从2017年8月到2023年5月）；Predictive Technology Group, Inc.，一家公共分子诊断和再生医学公司，从2019年2月至2019年12月；Osiris Therapeutics, Inc.，一家公共生物外科公司，从2006年5月到2017年12月；2012年11月至2014年8月，他担任美国公司（现SINTX Technologies， Inc.），一家公共骨科植入物公司。2013年10月至2014年8月，他担任美国首席财务官。从2008年5月到2009年7月，Moyes先生担任XDx（现为CareDx）， Inc.（一家私营分子诊断公司）的首席财务官。在此之前，他从1996年6月到2007年11月担任Myriad Genetics， Inc.（公共医疗保健诊断公司）的首席财务官，并从1993年7月到2005年7月担任财务副总裁。从1991年到1993年，Moyes先生担任Genmark， Inc.（一家私人控股的基因公司）的财务副总裁和首席财务官。1979年至1991年，他在毕马威会计师事务所担任多个职位，最近担任高级经理。他持有Utah大学的工商管理硕士学位，Weber State大学的经济学学士学位，并曾是一名注册会计师。他也曾担任the Utah Life Science Association的董事会成员（从1999年到2006年）。
- Jay M. Moyes,has also served on the board of directors of Puma Biotechnology, Inc. a public biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Mr. Moyes has been a member of the board of directors of Biocardia, Inc., a public cardiovascular regenerative medicine company, since January 2011. Mr. Moyes served as the Chief Financial Officer of Sera Prognostics, Inc., a public commercial-stage biotechnology company focused on improving maternal and neonatal health through innovative biomarker approaches, from March 2020 to June 2023. Mr. Moyes previously served as a member of the board of directors of Achieve Life Sciences, Inc., a public specialty pharmaceutical company, from August 2017 to May 2023; Predictive Technology Group, Inc., a public molecular diagnostics and regenerative medicine company, from February 2019 to December 2019; Osiris Therapeutics, Inc., a public bio-surgery company, from May 2006 until December 2017; and Amedica Corporation (now SINTX Technologies, Inc.), a public orthopedic implant company, from November 2012 to August 2014. He served as Chief Financial Officer of Amedica from October 2013 to August 2014. From May 2008 through July 2009, Mr. Moyes served as Chief Financial Officer of XDx (now CareDx), Inc., a privately held molecular diagnostics company. Prior to that, Mr. Moyes served as Chief Financial Officer of Myriad Genetics, Inc., a public healthcare diagnostics company, from June 1996 until November 2007, and as its Vice President of Finance from July 1993 until July 2005. From 1991 to 1993, Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc., a privately held genetics company. Mr. Moyes held various positions with the accounting firm of KPMG LLP from 1979 through 1991, most recently as a Senior Manager. He holds an M.B.A. from the University of Utah, a B.A. in economics from Weber State University, and is formerly a Certified Public Accountant. Mr. Moyes also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 through 2006.
- Hans Georg Klingemann
-
Hans Georg Klingemann，2012年当选为本公司董事。他曾担任波士顿Tufts Medical Center骨髓和干细胞移植项目的主任，目前是该校的教授。来到波士顿之前，他曾是Rush University Medical Center骨髓移植和细胞治疗项目的主任，也曾是伊利诺斯州芝加哥Sramek Center for Cell Engineering 的创始主任。20多年来，他作为医生、科学家、教育家、管理者，在欧洲和北美的各种学术医疗中心担任过领导职务；已撰写了170多篇科学与医学方面的文章。最近，他被任命为Conkwest的首席医学与科学官，这是他在2002年创办的细胞治疗公司。他获得了德国Würzburg Medical School 的医学博士学位、德国University of Marburg的博士学位。他是审核、审核与提名委员会的成员。
Hans Georg Klingemann elected to the Board of Directors in 2012 is the former Director of the Bone Marrow and Stem Cell Transplant Program at Tufts Medical Center in Boston where he maintains a professorship at the University. Before coming to Boston, Dr. Klingemann served as Director of Bone Marrow Transplant and Cell Therapy at Rush University Medical Center, and founding Director of the Sramek Center for Cell Engineering in Chicago, Illinois. He has worked as a physician, scientist, educator and administrator in leadership positions for over twenty years at various academic medical centers in Europe and North America and has authored over 170 scientific and medical papers. Recently he was appointed Chief Medical and Scientific Officer of Conkwest Inc., the cell therapy company he founded in 2002. Dr. Klingemann received his M.D. from the University of Wurzburg Medical School, Germany, and his Ph.D. from the University of Marburg, Germany. - Hans Georg Klingemann，2012年当选为本公司董事。他曾担任波士顿Tufts Medical Center骨髓和干细胞移植项目的主任，目前是该校的教授。来到波士顿之前，他曾是Rush University Medical Center骨髓移植和细胞治疗项目的主任，也曾是伊利诺斯州芝加哥Sramek Center for Cell Engineering 的创始主任。20多年来，他作为医生、科学家、教育家、管理者，在欧洲和北美的各种学术医疗中心担任过领导职务；已撰写了170多篇科学与医学方面的文章。最近，他被任命为Conkwest的首席医学与科学官，这是他在2002年创办的细胞治疗公司。他获得了德国Würzburg Medical School 的医学博士学位、德国University of Marburg的博士学位。他是审核、审核与提名委员会的成员。
- Hans Georg Klingemann elected to the Board of Directors in 2012 is the former Director of the Bone Marrow and Stem Cell Transplant Program at Tufts Medical Center in Boston where he maintains a professorship at the University. Before coming to Boston, Dr. Klingemann served as Director of Bone Marrow Transplant and Cell Therapy at Rush University Medical Center, and founding Director of the Sramek Center for Cell Engineering in Chicago, Illinois. He has worked as a physician, scientist, educator and administrator in leadership positions for over twenty years at various academic medical centers in Europe and North America and has authored over 170 scientific and medical papers. Recently he was appointed Chief Medical and Scientific Officer of Conkwest Inc., the cell therapy company he founded in 2002. Dr. Klingemann received his M.D. from the University of Wurzburg Medical School, Germany, and his Ph.D. from the University of Marburg, Germany.
高管简历
中英对照 | 中文 | 英文- Jonathan M. Hopper
Jonathan M. Hopper，他于2014年11月加入我们，担任我们的首席医疗官。他曾在英国从事医学实践25年以上，是一个创伤和矫形外科医生。从2010年8月到加入Osiris公司，他曾担任Stryker Corp.的副总裁兼全球医疗董事，为临床风险管理和产品开发事务提供建议。加入Stryker公司之前，他曾担任ConvaTec公司的多种医疗事务职务4年半，最终担任负责北美和亚太医务副总裁。
Jonathan M. Hopper joined us in November 2014 as our Chief Medical Officer. Dr Hopper has practiced medicine for over 25-years, primarily in the United Kingdom where he was a trauma and orthopaedic surgeon. From August 2010 until joining Osiris, Dr. Hopper served as the Vice President and Global Medical Director for Stryker Corp., advising on matters of clinical risk management and product development. Prior to joining Stryker, Dr. Hopper spent four and a half years in various medical affairs roles for ConvaTec Inc., eventually serving as Vice President of Medical Affairs, North America and Asia Pacific.- Jonathan M. Hopper，他于2014年11月加入我们，担任我们的首席医疗官。他曾在英国从事医学实践25年以上，是一个创伤和矫形外科医生。从2010年8月到加入Osiris公司，他曾担任Stryker Corp.的副总裁兼全球医疗董事，为临床风险管理和产品开发事务提供建议。加入Stryker公司之前，他曾担任ConvaTec公司的多种医疗事务职务4年半，最终担任负责北美和亚太医务副总裁。
- Jonathan M. Hopper joined us in November 2014 as our Chief Medical Officer. Dr Hopper has practiced medicine for over 25-years, primarily in the United Kingdom where he was a trauma and orthopaedic surgeon. From August 2010 until joining Osiris, Dr. Hopper served as the Vice President and Global Medical Director for Stryker Corp., advising on matters of clinical risk management and product development. Prior to joining Stryker, Dr. Hopper spent four and a half years in various medical affairs roles for ConvaTec Inc., eventually serving as Vice President of Medical Affairs, North America and Asia Pacific.
- Gregory I. Law
Gregory I. Law，他于2014年11月加入Osiris公司，担任我们的财务副总裁兼首席会计官。他拥有25年以上的多种行业财务和会计经验，涉及生物技术、电信、能源、私人股本和咨询。任职Osiris公司之前，他曾担任Garland Group的负责人，在那里他提供公共和私人公司咨询服务，涉及临时首席财务官和管理员职位、财务报表、合并和收购、估值和遵从性领域。此前，他曾担任龙头企业（如XO Communications公司、MCI公司、General Electric公司）的多种财务职务。他持有Virginia Tech的会计学士学位，以及George Washington University的工商管理硕士学位。
Gregory I. Law joined Osiris in November 2014 as our Vice President of Finance and Principal Accounting Officer. Mr. Law has over 25 years of finance and accounting experience in a variety of industries including biotechnology, telecommunications, energy, private equity, and consulting. Prior to his appointment at Osiris, Mr. Law was a Principal with Garland Group, where he provided consulting services to public and private companies in the areas of interim CFO and Controllership, financial reporting, mergers & acquisitions, valuation and compliance. Previously, Mr. Law held various finance positions at leading companies, such as XO Communications, MCI and General Electric. He graduated from Virginia Tech with a B.S. in Accounting and earned his M.B.A. from George Washington University.- Gregory I. Law，他于2014年11月加入Osiris公司，担任我们的财务副总裁兼首席会计官。他拥有25年以上的多种行业财务和会计经验，涉及生物技术、电信、能源、私人股本和咨询。任职Osiris公司之前，他曾担任Garland Group的负责人，在那里他提供公共和私人公司咨询服务，涉及临时首席财务官和管理员职位、财务报表、合并和收购、估值和遵从性领域。此前，他曾担任龙头企业（如XO Communications公司、MCI公司、General Electric公司）的多种财务职务。他持有Virginia Tech的会计学士学位，以及George Washington University的工商管理硕士学位。
- Gregory I. Law joined Osiris in November 2014 as our Vice President of Finance and Principal Accounting Officer. Mr. Law has over 25 years of finance and accounting experience in a variety of industries including biotechnology, telecommunications, energy, private equity, and consulting. Prior to his appointment at Osiris, Mr. Law was a Principal with Garland Group, where he provided consulting services to public and private companies in the areas of interim CFO and Controllership, financial reporting, mergers & acquisitions, valuation and compliance. Previously, Mr. Law held various finance positions at leading companies, such as XO Communications, MCI and General Electric. He graduated from Virginia Tech with a B.S. in Accounting and earned his M.B.A. from George Washington University.
- Alla N. Danilkovitch
Alla N. Danilkovitch，他曾成功推出产品开发科学思想市场，包括用于移植物抗宿主疾病的世界上第一个批准干细胞药物Prochymal，以及Osiris公司的当前系列产品。加入Osiris公司之前，他曾在以下机构从事研究：National Cancer Institute of National Institutes of Health、Max-Plank Institute of Biochemistry（位于德国慕尼黑）、Eotvos Lorand University（位于匈牙利布达佩斯）、Moscow State University（位于俄罗斯）。他持有the Moscow State University的细胞生物学博士学位、细胞免疫学和微生物学硕士学位。他持有印度儿科学位，拥有Moscow公司的俄罗斯省总医院重症监护经验。
Alla N. Danilkovitch has a proven record of successful product development from scientific ideas to market launch, which includes the world's first approved stem cell drug, Prochymal, for graft versus host disease as well as Osiris' current line of products. Prior to joining Osiris, Dr. Danilkovitch conducted research at the following institutions: National Cancer Institute of National Institutes of Health, Max-Plank Institute of Biochemistry in Munich Germany, Eotvos Lorand University in Budapest (Hungary) and Moscow State University (Russia). Dr. Danilkovitch earned a Ph.D. degree in cell biology and an M.S. degree in cellular immunology and microbiology from the Moscow State University. She also holds a R.N. degree in pediatrics with an intensive care experience at Moscow's province general hospital in Russia.- Alla N. Danilkovitch，他曾成功推出产品开发科学思想市场，包括用于移植物抗宿主疾病的世界上第一个批准干细胞药物Prochymal，以及Osiris公司的当前系列产品。加入Osiris公司之前，他曾在以下机构从事研究：National Cancer Institute of National Institutes of Health、Max-Plank Institute of Biochemistry（位于德国慕尼黑）、Eotvos Lorand University（位于匈牙利布达佩斯）、Moscow State University（位于俄罗斯）。他持有the Moscow State University的细胞生物学博士学位、细胞免疫学和微生物学硕士学位。他持有印度儿科学位，拥有Moscow公司的俄罗斯省总医院重症监护经验。
- Alla N. Danilkovitch has a proven record of successful product development from scientific ideas to market launch, which includes the world's first approved stem cell drug, Prochymal, for graft versus host disease as well as Osiris' current line of products. Prior to joining Osiris, Dr. Danilkovitch conducted research at the following institutions: National Cancer Institute of National Institutes of Health, Max-Plank Institute of Biochemistry in Munich Germany, Eotvos Lorand University in Budapest (Hungary) and Moscow State University (Russia). Dr. Danilkovitch earned a Ph.D. degree in cell biology and an M.S. degree in cellular immunology and microbiology from the Moscow State University. She also holds a R.N. degree in pediatrics with an intensive care experience at Moscow's province general hospital in Russia.
- Philip R. Jacoby, Jr.
Philip R. Jacoby, Jr.，2009年7月起担任本公司首席财务官；2010年5月起，担任财务总管；2007年11月起，担任企业秘书。他于2005年4月加入本公司，担任顾问方面的职务；2005年10月，成为本公司雇员。之前，他曾担任本公司的财务副总裁、企业财务总监、首席会计官。1999-2004，他曾担任FTI Consulting的副总裁、企业财务总监，这是一个全球性的商业财务与经济咨询公司。职业生涯之初，他任职于Arthur Andersen & Co.。他在University of Maryland获得商业与公共管理本科学位。
Philip R. Jacoby, Jr. is our Chief Financial Officer since July 2009 Treasurer (since May 2010) and Corporate Secretary (since November 2007). Mr. Jacoby joined us in a consulting capacity in April 2005 and became our employee in October 2005. Mr. Jacoby previously served as our Vice President of Finance, Corporate Controller and Chief Accounting Officer. From 1999 to 2004 Mr. Jacoby served as Vice President and Corporate Controller for FTI Consulting, Inc., a global business financial and economic consulting firm. Mr. Jacoby began his career with Arthur Andersen & Co. and earned his undergraduate degree in business and public administration from the University of Maryland.- Philip R. Jacoby, Jr.，2009年7月起担任本公司首席财务官；2010年5月起，担任财务总管；2007年11月起，担任企业秘书。他于2005年4月加入本公司，担任顾问方面的职务；2005年10月，成为本公司雇员。之前，他曾担任本公司的财务副总裁、企业财务总监、首席会计官。1999-2004，他曾担任FTI Consulting的副总裁、企业财务总监，这是一个全球性的商业财务与经济咨询公司。职业生涯之初，他任职于Arthur Andersen & Co.。他在University of Maryland获得商业与公共管理本科学位。
- Philip R. Jacoby, Jr. is our Chief Financial Officer since July 2009 Treasurer (since May 2010) and Corporate Secretary (since November 2007). Mr. Jacoby joined us in a consulting capacity in April 2005 and became our employee in October 2005. Mr. Jacoby previously served as our Vice President of Finance, Corporate Controller and Chief Accounting Officer. From 1999 to 2004 Mr. Jacoby served as Vice President and Corporate Controller for FTI Consulting, Inc., a global business financial and economic consulting firm. Mr. Jacoby began his career with Arthur Andersen & Co. and earned his undergraduate degree in business and public administration from the University of Maryland.
- Lode Debrabandere
Lode Debrabandere，2013年12月，晋升为本公司的总裁、首席执行官。他于2006年7月加入本公司，担任副总裁、治疗总经理；2012年10月，他成为首席运营官。为了填补C. Randal Mills辞职而留下的空缺，他在2014年1月当选为董事。他有着20多年的制药和生物技术行业的研发、销售及营销的领导经验。加入本公司之前，他曾担任Bristol Myers Squibb的全球营销副总裁，领导着神经科学部；也曾是Abilif的全球品牌经理。
Lode Debrabandere was promoted to serve as our President and Chief Executive Officer in December 2013. He joined us in July 2006 as our Vice President and General Manager of Therapeutics. He became our Chief Operating Officer in October 2012 and was elected to our Board of Directors in January 2014. Dr. Debrabandere has over 20-years of experience leading R&D and sales and marketing activities in the pharmaceutical and biotechnology industries. Prior to joining us, he served as Vice President of Global Marketing of Bristol Myers Squibb where he led the Neuroscience Unit and was the Global Brand Manager for Abilify™. He currently serves on the Board of Directors of Prolexys Pharmaceuticals, Inc.- Lode Debrabandere，2013年12月，晋升为本公司的总裁、首席执行官。他于2006年7月加入本公司，担任副总裁、治疗总经理；2012年10月，他成为首席运营官。为了填补C. Randal Mills辞职而留下的空缺，他在2014年1月当选为董事。他有着20多年的制药和生物技术行业的研发、销售及营销的领导经验。加入本公司之前，他曾担任Bristol Myers Squibb的全球营销副总裁，领导着神经科学部；也曾是Abilif的全球品牌经理。
- Lode Debrabandere was promoted to serve as our President and Chief Executive Officer in December 2013. He joined us in July 2006 as our Vice President and General Manager of Therapeutics. He became our Chief Operating Officer in October 2012 and was elected to our Board of Directors in January 2014. Dr. Debrabandere has over 20-years of experience leading R&D and sales and marketing activities in the pharmaceutical and biotechnology industries. Prior to joining us, he served as Vice President of Global Marketing of Bristol Myers Squibb where he led the Neuroscience Unit and was the Global Brand Manager for Abilify™. He currently serves on the Board of Directors of Prolexys Pharmaceuticals, Inc.
- Frank D. Czworka, Jr.
Frank D. Czworka, Jr.，于2011年加入Osiris并担任Wound Care总经理；于2014年2月被提升为副总裁。他拥有着生命科学行业超过20年的销售和营销经验，主要在受监管的市场建立专门销售团队和开发产品数据库（包括公共和私有付款方账户）。Czworka先生曾于2009至2011年间，在Auxillium Pharmaceuticals工作；2000至2009年间，在MedImmune有限责任公司担任副总裁。他拥有从中佛罗里达大学（University of Central Florida）获得的市场营销学士学位。
Frank D. Czworka, Jr. joined Osiris in 2011 as General Manager of Wound Care and was promoted to Vice President in February 2014. Mr. Czworka has over 20 years of sales and marketing experience in the Life Science industry with a demonstrated track record of building specialty sales forces and developing product access in managed markets, including public and private payer accounts. Mr. Czworka worked for Auxillium Pharmaceuticals from 2009 through 2011 and was Vice President of Sales at MedImmune, LLC from 2000 through 2009. He holds a BSBA degree in Marketing from the University of Central Florida.- Frank D. Czworka, Jr.，于2011年加入Osiris并担任Wound Care总经理；于2014年2月被提升为副总裁。他拥有着生命科学行业超过20年的销售和营销经验，主要在受监管的市场建立专门销售团队和开发产品数据库（包括公共和私有付款方账户）。Czworka先生曾于2009至2011年间，在Auxillium Pharmaceuticals工作；2000至2009年间，在MedImmune有限责任公司担任副总裁。他拥有从中佛罗里达大学（University of Central Florida）获得的市场营销学士学位。
- Frank D. Czworka, Jr. joined Osiris in 2011 as General Manager of Wound Care and was promoted to Vice President in February 2014. Mr. Czworka has over 20 years of sales and marketing experience in the Life Science industry with a demonstrated track record of building specialty sales forces and developing product access in managed markets, including public and private payer accounts. Mr. Czworka worked for Auxillium Pharmaceuticals from 2009 through 2011 and was Vice President of Sales at MedImmune, LLC from 2000 through 2009. He holds a BSBA degree in Marketing from the University of Central Florida.